Vemurafenib in Combination with the MEK inhibitor, GDC-0973 in BRAFV600 Mutation pos Melanoma
Channel: Oncoletter
Date: 29/09/2012

Vienna, ESMO 2012, Pressconference September 29: Prof Rene Gonzalez, Division Of Medical Oncology, University of Colorado, Aurora/UNITED STATES OF AMERICA
Phase IB Study of Vemurafenib in Combination with the MEK inhibitor, GDC-0973, in Patients with Locally Advanced/Unresectable or Metastatic BRAFV600 Mutation Positive Melanoma.